Your browser doesn't support javascript.
loading
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
van Vollenhoven, Ronald; Strand, Vibeke; Takeuchi, Tsutomu; Chávez, Nilmo; Walter, Pablo Mannucci; Singhal, Atul; Swierkot, Jerzy; Khan, Nasser; Bu, Xianwei; Li, Yihan; Penn, Sara K; Camp, Heidi S; Aelion, Jacob.
Afiliación
  • van Vollenhoven R; Amsterdam University Medical Centers, Amsterdam, Netherlands. r.vanvollenhoven@amsterdamumc.nl.
  • Strand V; Division Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA.
  • Takeuchi T; Keio University School of Medicine, Tokyo, Japan.
  • Chávez N; Saitama Medical University, Saitama, Japan.
  • Walter PM; Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala.
  • Singhal A; Aprillus Asistencia e Investigación, Buenos Aires, Argentina.
  • Swierkot J; Southwest Rheumatology Research Group, Dallas, TX, USA.
  • Khan N; Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
  • Bu X; AbbVie Inc, North Chicago, IL, USA.
  • Li Y; AbbVie Inc, North Chicago, IL, USA.
  • Penn SK; AbbVie Inc, North Chicago, IL, USA.
  • Camp HS; AbbVie Inc, North Chicago, IL, USA.
  • Aelion J; AbbVie Inc, North Chicago, IL, USA.
Arthritis Res Ther ; 26(1): 143, 2024 Jul 29.
Article en En | MEDLINE | ID: mdl-39075620
ABSTRACT

BACKGROUND:

To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial.

METHODS:

Patients were randomized to receive upadacitinib 15 mg or 30 mg or MTX. Patients who did not achieve CDAI remission and had < 20% improvement in tender and swollen joint counts at week 26 received rescue therapy (addition of MTX in the upadacitinib group and addition of upadacitinib in the MTX group). Efficacy assessments were evaluated over 5 years and are reported as observed (AO) for patients who received continuous monotherapy with upadacitinib 15/30 mg or MTX and by randomized group applying non-responder imputation (NRI). Treatment-emergent adverse events (TEAEs) per 100 patient-years were summarized over 5 years.

RESULTS:

Of 945 patients randomized and treated, 775 (82%) completed week 48 and entered the LTE on study drug. Higher proportions of patients consistently achieved disease activity targets over 5 years with upadacitinib than MTX. In AO analyses, 53%/59% of patients attained CDAI remission with upadacitinib 15/30 mg versus 43% with MTX at week 260. NRI analyses showed better CDAI, DAS28(CRP), and ACR responses with upadacitinib relative to MTX at week 260 (all comparisons, nominal P < .001). Upadacitinib treatment also resulted in numerically greater inhibition of structural joint progression through week 260 compared to MTX. Most TEAEs, serious AEs, and AEs leading to discontinuation were numerically higher in patients receiving upadacitinib 30 mg. Rates of serious infections, herpes zoster, creatine phosphokinase elevation, nonmelanoma skin cancer, and neutropenia were numerically higher with upadacitinib than MTX. The observed safety profile of upadacitinib over 5 years was consistent with earlier trial results and integrated phase 3 safety analyses.

CONCLUSIONS:

Upadacitinib showed better clinical responses versus MTX in patients with RA throughout the 5-year trial. Higher rates of several AEs were observed with upadacitinib, especially in the 30 mg group, compared to MTX. When used as monotherapy in MTX-naïve patients, the approved upadacitinib 15 mg dose showed better long-term efficacy versus MTX and an overall favorable benefit-risk profile. TRIAL REGISTRATION NCT02706873.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Metotrexato / Antirreumáticos / Compuestos Heterocíclicos con 3 Anillos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Metotrexato / Antirreumáticos / Compuestos Heterocíclicos con 3 Anillos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos